Tandem Diabetes Care Announces Second Quarter 2019 Financial Results and Updated 2019 Financial Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil drops $1 as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Tandem Diabetes (TNDM) Tops Q2 EPS by 22c, Revenues Beat; Offers FY19 Sales Outlook Above Consensus
August 1, 2019 5:08 PM EDTTandem Diabetes (NASDAQ: TNDM) reported Q2 EPS of ($0.03), $0.22 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $93.26 million versus the consensus estimate of $70.03 million.
In comparing the second quarter of 2019 to the same period of 2018:
Worldwide pump shipments increased 290 percent to 21,258 pumps from 5,447 pumpsSales increased 173 percent to $93.3 million from $34.1 millionOperating margin improved to negative 2 percent from negative 41 percentAdjusted EBITDA(1) improved to 13 percent of sales from negative 29 percent of salesWe shipped more pumps in... More
